Impact ledger
Halozyme Therapeutics, Inc. (HALO)
2 events mapped to this ticker since 2026-06-22.
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-06-22 | Event | Increased sales of XYOSTED through the co-marketing collaboration with LifeMD could lead to higher royalty or supply revenue for Halozyme (via its Antares Pharma subsidiary). | Bullish | 1-3m | 0.60 |
| 2026-06-22 | Event | The collaboration's success is tied to LifeMD's execution. If the direct-to-patient program underperforms, the expected revenue uplift for Halozyme could be lower than anticipated, potentially impacting future guidance. | watch | 3-12m | 0.30 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for HALO, start a trial or view the HALO entity page.